I would doubt it in terms of potency. Simeprevir's greatest attribute is its late stage of development. Followed by a few notable oral studies with other companies and a partner willing to market the drug internationally. It's not going to be a hard drug beat for competitors, as sofosbuvir is within the nucleotide class.
Market Data 
Markets 
AI
